84 related articles for article (PubMed ID: 26689512)
1. Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey.
Uçer O; Yücetas U; Çelen I; Toktas G; Müezzinoglu T
Int Braz J Urol; 2015; 41(5):864-8. PubMed ID: 26689512
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings.
Patel S; Issa MM; El-Galley R
Urology; 2013 Mar; 81(3):602-6. PubMed ID: 23312893
[TBL] [Abstract][Full Text] [Related]
3. New indicator for prostate gland biopsy when malignancy is in question.
Haroun AA
Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):61-6. PubMed ID: 21196614
[TBL] [Abstract][Full Text] [Related]
4. A higher PSA-density cut-off level in patients with intermediate PSA values for the early detection of prostate cancer.
Mochtar CA; Rahardjo D; Umbas R
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():514-22. PubMed ID: 10895203
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases.
Kang SH; Bae JH; Park HS; Yoon DK; Moon DG; Kim JJ; Cheon J
Int J Urol; 2006 Jul; 13(7):910-4. PubMed ID: 16882054
[TBL] [Abstract][Full Text] [Related]
6. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?
Kim JS; Ryu JG; Kim JW; Hwang EC; Jung SI; Kang TW; Kwon D; Park K
Int Braz J Urol; 2015; 41(2):258-64. PubMed ID: 26005966
[TBL] [Abstract][Full Text] [Related]
8. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
[TBL] [Abstract][Full Text] [Related]
9. [Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy].
Rodríguez-Patrón Rodríguez R; Mayayo Dehesa T; González Galán A; Zuccarino AL; García González R; Cuesta Roca C
Arch Esp Urol; 2002 Dec; 55(10):225-34. PubMed ID: 12611220
[TBL] [Abstract][Full Text] [Related]
10. PSA density improves prediction of prostate cancer.
Verma A; St Onge J; Dhillon K; Chorneyko A
Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363
[TBL] [Abstract][Full Text] [Related]
11. [Multiple prostatic biopsies in the "gray zone" of the specific prostatic antigen].
Drudi FM; Ricci P; Iannicelli E; Di Nardo R; Novelli L; Laghi A; Perugia G; Passariello R
Radiol Med; 2000; 99(1-2):81-5. PubMed ID: 10803192
[TBL] [Abstract][Full Text] [Related]
12. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
13. Is the diagnostic yield of prostate needle biopsies affected by prostate volume?
Leibovici D; Shilo Y; Raz O; Stav K; Sandbank J; Segal M; Zisman A
Urol Oncol; 2013 Oct; 31(7):1003-5. PubMed ID: 21924650
[TBL] [Abstract][Full Text] [Related]
14. Is PSA density still useful in diagnosing prostate cancer?
Pepe P; Candiano G; Fraggetta F; Galia A; Grasso G; Allegro R; Aragona F
Arch Ital Urol Androl; 2009 Dec; 81(4):199-202. PubMed ID: 20608140
[TBL] [Abstract][Full Text] [Related]
15. Length of prostate biopsy cores: does it impact cancer detection?
Fiset PO; Aprikian A; Brimo F
Can J Urol; 2013 Aug; 20(4):6848-53. PubMed ID: 23930611
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen as surrogate for the histological diagnosis of prostate cancer.
Heyns CF; Naudé AM; Ahmed G; Stopforth HB; Stellmacher GA; Visser AJ
S Afr Med J; 2001 Aug; 91(8):685-9. PubMed ID: 11584785
[TBL] [Abstract][Full Text] [Related]
17. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
18. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
20. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
